Modafinil: a novel stimulant for the treatment of narcolepsy

Bibliography

• COLEMAN RM, ROFFWARG HP, KENNEDY SJ et al.: Sleep-wake disorders based on a polysomnographic diagno-sis. A national cooperative study. JAMA (1982) 247 (7) 997–1003.
   Web of Science ®Google Scholar
• BASSETTI C, ALDRICH MS: Narcolepsy. NeuroL Cl/n. (1996) 14(3):545–571.
   PubMed Web of Science ®Google Scholar
• NISHINO S, MIGNOT E: Pharmacological aspects of hu-man and canine narcolepsy. Prog, Neurobiol, (1997) 52(1)27–78.
   Google Scholar
• BROUGHTON R, GHANEM Q, HISHIKAWA Y etaL: Life ef-fects of narcolepsy in 180 patients from North Amer-ica, Asia and Europe compared to matched controls. Can. J. NeuroL Sci, (1981) 8 (4) :299–304.
   PubMed Web of Science ®Google Scholar
• BROUGHTON WA, BROUGHTON RJ: Psychosocial im-pact of narcolepsy. Sleep (1994) 17 (Suppl. 8):S45–49.
   Google Scholar
• Practice parameters for the use of stimulants in the treatment of narcolepsy. Standards of Practice Com-mittee of the American Sleep Disorders Association. Sleep (1994) 17(4):348–351.
   PubMedGoogle Scholar
• MITLER MM, ALDRICH MS, KOOB GF et al.: Narcolepsy and its treatment with stimulants. ASDA standards of practice. Sleep (1994) 17(4) :352–371.
   Google Scholar
• RAMBERT FA, PESSONNIER J, DE SEREVILLE JE et al.: A unique psychopharmacologic profile of adrafinil in mice. J. Pharmacol. (1986) 17 (1) :37–52.
   Google Scholar
• GORMAN SH, NEIDLINGER SK, STONG DB et al.: Pharma- cokinetic profiles of modafinil and modafinil acid dur-ing a double-blind, ascending dose, seven day administration of modafinil tablets in normal male subjects. 6th N. Am. ISSX Meeting. Raleigh (1994).
   Google Scholar
• MOACHON G, KANMACHER I, CLENET M et al.: Pharma-cokinetic profile of modafinil. Drugs of Today (1996) 32 (4) :327–337.
   Web of Science ®Google Scholar
• WONG YN, GORMAN S, MCCORMICK GC et al.: Single-dose pharmacokinetics of modafinil and meth-ylphenidate given alone and in combination to healthy male volunteers. APSSAnnual Meeting. San Fran-cisco (1997).
   Google Scholar
• KANMACHER I, BARTHOUX N, MILLET P et al.: Metabo-lism of modafinil in mice, rats, guinea pigs, and rab-bits. 1st European Congress of Pharmacology. Milan, Italy (1995).
   Google Scholar
• GROZINGER M, HARTTER S, HIERNKE C et al.: Does mo-dafinil increase the blood level of tricyclic antidepres-sive comedication without lorazepam medication? Third International Meeting on Sleep Disorders. Bordeaux, France (1997).
   Google Scholar
• WONG YN, GORMAN S, SIMCOE D et al A double-blind, placebo-controlled crossover study to investigate the kinetics and acute tolerability of modafinil and clomi-pramine alone and in combination in healthy male volunteers. APSS Annual Meeting San Francisco, USA (1997)
   Google Scholar
• LE CACHEUX P, CHARASSE C, MOURTADA R et al.: Ge-lineau syndrome in a patient with renal transplanta-tion. Evidence of cyclosporine-modafinil interaction. Presse Med. (1997) 26(10):466.
   PubMedGoogle Scholar
• LIN JS, ROUSSEL B, AKAOKA H et al.: Role of catechola-mines in the modafinil and amphetamine induced wakefulness, a comparative pharmacological study in the cat. Brain Res. (1992) 591 (2) :319–326.
   PubMed Web of Science ®Google Scholar
• AKAOKA H, ROUSSEL B, LIN JS et al.: Effect of modafinil and amphetamine on the rat catecholaminergic neu-ron activity. Neurosci, Lett. (1991) 123(0:20–22.
   PubMedGoogle Scholar
• MIGNOT E, NISHINO S, GUILLEMINAULT C et al.: Modaf-inil binds to the dopamine uptake carrier site with low affinity. Sleep (1994) 17 (5) :436–437.
   PubMed Web of Science ®Google Scholar
• CONTRERAS PC, EDGAR DM, MIGNOT E et al.: A compari-son of the preclinical pharmacology of modafinil and amphetamine-like drugs. Congress on Problems in Drug Dependence. Nashville, USA (1997).
   Google Scholar
• FERRARO L, TANGANELLI S, O'CONNOR WT et al.: The vigilance promoting drug modafinil increases dopa-mine release in the rat nucleus accumbens via the in-volvement of a local GABAergic mechanism. Eur, J. Pharmacol, (1996) 306 (1-3) :33–39.
   Google Scholar
• DE SEREVILLE JE, BOER C, RAMBERT FA et al.: Lack of pre-synaptic dopaminergic involvement in modafinil activity in anaesthetized mice: in vivo voltammetry studies. Neuropharmacology (1994) 33 (6) 755–761.
   PubMed Web of Science ®Google Scholar
• TANGANELLI S, FUXE K, FERRARO L et al.: Inhibitory ef-fects of the psychoactive drug modafinil on gamma-aminobutyric acid outflow from the cerebral cortex of the awake freely moving guinea-pig. Possible involve-ment of 5-hydroxytryptamine mechanisms. Naunyn Schmiedebergs Arch. Pharmacol. (1992) 345 (4):461–465.
   Google Scholar
• TANGANELLI S, PEREZ DE LA MORA M, FERRARO L et al.: Modafinil and cortical gamma-aminobutyric acid out-flow. Modulation by 5-hydroxytryptamine neurotox-ins. Eur, J. Pharmacol. (1995) 273 (1–2) :63–71.
   Google Scholar
• FERRARO L, TANGANELLI S, O'CONNOR WT et al.: Thevigilance promoting drug modafinil decreases GABA release in the medial preoptic area and in the poste-rior hypothalamus of the awake rat: possible involve-ment of the serotonergic 5-11T3 receptor. Neurosci, Lett. (1996) 220(0:5–8.
   Google Scholar
• FERRARO L, ANTONELLI T, O'CONNOR T et al.: The anti-narcoleptic drug modafinil increases glutamate re-lease in thalamic areas and hippocampus. NeuroReport (1997) 8:2883–2887.
   Google Scholar
• SHERIN JE, SHIROMANI PJ, MCCARLEY RW et al.: Activa-tion of ventrolateral preoptic neurones during sleep. Science (1996) 271 (5246):216–219.
   PubMed Web of Science ®Google Scholar
• LIN JS, SAKAI K, VANNI-MERCIER G et al.: A critical role of the posterior hypothalamus in the mechanisms of wakefulness determined by microinjection of musci-mol in freely moving cats. Brain Res. (1989) 479 (2) :225–240.
   PubMed Web of Science ®Google Scholar
• LIN JS, HOU Y, JOUVET M: Potential brain neuronal tar-gets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl. Acad. Sci. USA (1996) 93(24):14128–14133.
   PubMed Web of Science ®Google Scholar
• FUXE K, JANSON AM, ROSEN L et al.: Evidence for a pro- tective action of the vigilance promoting drug modaf-inil on the MPTP-induced degeneration of the nigrostriatal dopamine neurones in the black mouse: an immunocytochemical and biochemical analysis. Exp. Brain Res. (1992) 88(0:117–130.
   PubMedGoogle Scholar
• UEKI A, ROSEN L, ANDBJER B et al.: The vigilance-promoting drug modafinil counteracts the reduction of tyrosine hydroxylase immunoreactivity and of do-pamine stores in nigrostriatal dopamine neurones in the male rat after a partial transection of the dopamine pathway. Exp. Brain Res. (1993) 93(2):259–270.
   PubMed Web of Science ®Google Scholar
• UEKI A, ROSEN L, ANDBJER B et al.: Evidence for a pre-ventive action of the vigilance-promoting drug modaf-inil against striatal ischaemic injury induced by endothelin-1 in the rat. Exp. Brain Res. (1993) 96(1)89–99.
   Google Scholar
• EDGAR DM, SEIDEL WF: Modafinil induces wakefulnesswithout intensifying motor activity or subsequent re-bound hypersomnolence in the rat. J. Pharmacol. Exp. Then (1997) 283(2):757–769.
   PubMed Web of Science ®Google Scholar
• DUTEIL J, RAMBERT FA, PESSONNIER J et al. Central al- pha 1-adrenergic stimulation in relation to the behav-iour stimulating effect of modafinil; studies with experimental animals. Eur. J. Pharmacol (1990) 180(1)49–58.
   Google Scholar
• LAGARDE DPS, ANTON G: Comparative study of stimu-lant effects of d-amphetamine sulfate and modafinil, an original psychostimulant. Eur. J. Pharmacol. (1990) 183:1476.
   Web of Science ®Google Scholar
• TOURET M, SALLANON-MOULIN M, JOUVET M: Awaken-ing properties of modafinil without paradoxical sleep rebound: comparative study with amphetamine in the rat. Neurosci. Left (1995) 189(0:43–46.
   PubMedGoogle Scholar
• LEBRAND C, BOURGIN P, MAUDHUIT C et al.: Chronic treatment with modafinil in the rat effects on sleep-wakefulness cycles. Sleep Res. (1995) 24A:131.
   Google Scholar
• LAGARDE D, MILHAUD C: Electroencephalographic ef-fects of modafinil, an alpha-l-adrenergic psy-chostimulant, on the sleep of rhesus monkeys. Sleep (1990) 13(5):441–448.
   PubMed Web of Science ®Google Scholar
• PANCKERI KA, SCHOTLAND HM, PACK Al et al.: Modaf-inil decreases hypersomnolence in the English bull-dog, a natural animal model of sleep-disordered breathing. Sleep (1996) 19(8):626–631.
   PubMed Web of Science ®Google Scholar
• SHELTON J, NISHINO S, VAUGHT J et al.: Comparative ef-fects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs. Sleep (1995) 18(10):817–826.
   PubMed Web of Science ®Google Scholar
• LAGARDE D, BATEJAT D, VAN BEERS P et al.: Interest ofmodafinil, a new psychostimulant, during a sixty-hour sleep deprivation experiment. Fundam Pharmacol. (1995) 9(3):271–279.
   Google Scholar
• BUGUET A, MONTMATYEUR A, PIGEAU R et al.: Modaf-inil, d-amphetamine and placebo during 64 hours of sustained mental work. II. Effects of two nights of re-covery sleep. J. Sleep Res. (1995) 4:229–241.
   Google Scholar
• GOLDENBERG F: Refinement of an EEG diurnal vigi-lance index. Application to drug trials. Rev. Electroen-cephaL Neurophys. Clin. (1986) 16(0:39–48.
   Google Scholar
• GOLDENBERG F, WEIL JS AND VON FRENCKEEL R: Ef-fects of modafinil on diurnal variation of objective sleepiness in normal subjects. Fifth International Con-gress on Sleep Research. Copenhagen, Denmark (1987).
   Google Scholar
• SALETU B, GRUNBERGER J, LINZMAYER L et al.: Pharmaco-EEG, psychometric and plasma level stud-ies with two a-adrenergic stimulants CRL 40–476 and adrafinil in elderlies. In: New Trends in Experimental and Clinical Psychiatry Pancheri P (Ed.), (1986):5–31.
   Google Scholar
• GOLDENBERG F: Study of the effects of 200 mg of mo-dafinil on performances, daytime alertness, and night-time sleep in comparison with a placebo. Clinical Expert Report, Laboratoire Lafon, (1985).
   Google Scholar
• CARSKADON MA, DEMENT WC, MITLER MM et al.: Guide-lines for the multiple sleep latency test (MSLT): a stan-dard measure of sleepiness. Sleep (1986) 9(4):519–524.
   PubMed Web of Science ®Google Scholar
• PIGEAU R, NAITOH P, BUGUET A et al.: Modafinil, d-amphetamine, and placebo during 64 hours of sus-tained mental work. I. Effects on mood, fatigue, cogni-tive performance and body temperature. J. Sleep Res. (1995) 4:212–228.
   Google Scholar
• BASTUJI H, JOUVET M: Successful treatment of idio-pathic hypersomnia and narcolepsy with modafinil. Prog. Neuropsychopharmacol. Biol. Psychiat. (1988) 12(5)695–700.
   Google Scholar
• LAFFONT F, MAYER G, MINZ M: Modafinil in diurnalsleepiness. A study of 123 patients. Sleep (1994) 17 (Suppl 8):S113–115.
   Google Scholar
• BESSET A, CHETRIT M, CARLANDER B et al.: Use of mo-dafinil in the treatment of narcolepsy: a long term follow-up study. NeurophysioL Clin. (1996) 26(1)60–66.
   Google Scholar
• ARNULF I, HOMEYER P, GARMA L et al.: Modafinil in ob-structive sleep apnoea-hypopnea syndrome: a pilot study in 6 patients. Respiration (1997) 64(2)159–161.
   Google Scholar
• YOUNG T, PALTA M, DEMPSEY J et al.: The occurrence ofsleep-disordered breathing among middle-aged adults. New. Engl. J. Med. (1993) 328(17):1230–1235.
   PubMed Web of Science ®Google Scholar
• BOIVIN DB, MONTPLAISIR J, PETIT D et al.: Effects of mo-dafinil on symptomatology of human narcolepsy. Neuropharmacol. (1993) 16(0:46–53.
   Google Scholar
• BILLIARD M, BESSET A, MONTPLAISIR J etaL: Modafinil: adouble-blind multicentric study. Sleep (1994) 17\(Suppl. 8):S107–112.
   Google Scholar
• BROUGHTON RJ, FLEMING JA, GEORGE CF et al Ran- domised, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive day-time sleepiness in narcolepsy. Neurology (1997) 49(2)444–451.
   Google Scholar
• FRY J: A new alternative in the pharmacologic manage-ment of somnolence: a Phase III study of modafinil in narcolepsy. Ann. Neurol. (1996) 40(3):493.
   Google Scholar
• GROSS PT: Modafinil: a new treatment for excessivedaytime somnolence (EDS) in patients with narco-lepsy. Neurology (1997) 48:A278.
   Google Scholar
• MITLER MM, GUJAVARTY KS, BROWMAN CP: Mainte-nance of wakefulness test: a polysomnographic tech-nique for evaluating treatment efficacy in patients with excessive somnolence. ElectroencephaL Din. Neu-rophysiol. (1982) 53 (6) :658–661.
   PubMed Web of Science ®Google Scholar
• GUY W: ECDEU Assessment Manual for Psychopharmacol-ogy (Revised). US Department of Health, Education, and Welfare; Public Health Service; Alcohol, Drug Abuse, and Mental Health Administration; National Institute of Mental Health; Psychopharmacology Research Branch, Rockville, MD (1976).
   Google Scholar
• MCNAIR DM, LORR M, DROPLEMAN LF: Profile of moodstates manual. Educational and Industrial Testing Service, San Diego, USA (1992).
   Google Scholar
• JASINSKI DR: An evaluation of the abuse potential ofmodafinil using methylphenidate as a reference. In: Congress on Problems in Drug Dependence. Nashville, USA (1997).
   Google Scholar
• SALETU B, FREY R, KRUPKA M et al.: Differential effects of the new central adrenergic agonist modafinil and d-amphetamine on sleep and early morning behav-iour in elderlies. Arzneimittelforschung (1989) 39 (10):1268–1273.
   PubMed Web of Science ®Google Scholar
• SALETU B, FREY R, KRUPKA M et al.: Differential effects of a new central adrenergic agonist -modafinil and D-amphetamine on sleep and early morning behaviour in young healthy volunteers. Intl. Clin. Pharmacol. Res. (1989) 9(3):183–195.
   PubMed Web of Science ®Google Scholar
• WAROT D, CORRUBLE E, WEIL JS et al.: Subjective effects of psychostimulant drugs in healthy volunteers: a comparison of modafinil, amphetamine, caffeine, and placebo. Fundam. Clin. Pharmacol. (1992) 6:412.
   Google Scholar
• GOLD LH, BALSTER RL: Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil. Psychopharmacology (1996) 126(4) 286–292.
   PubMed Web of Science ®Google Scholar